SCHEMBL7910491

SCHEMBL7910491

C[C@H](NC(=O)C1(c2ccccc2)CCN(C(=O)c2cnc(N3CCOCC3)s2)CC1)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OGA O60502 4/20 0.49
TP53 P04637 1/20 0.45
HTT P42858 1/20 0.45
ALDH1A1 P00352 1/20 0.44
MLYCD O95822 4/20 0.44
HDAC3 O15379 1/20 0.42
HDAC4 P56524 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC7 Q8WUI4 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC10 Q969S8 1/20 0.42
HDAC11 Q96DB2 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
HDAC9 Q9UKV0 1/20 0.42
HDAC5 Q9UQL6 1/20 0.42
MAPK1 P28482 1/20 0.41
TSHR P16473 1/20 0.41
ATM Q13315 1/20 0.41
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3096819 0.85 MLYCD (0.54) OGAALDH1A1MLYCDHDAC3HDAC4
SCHEMBL7909073 0.82 ALDH1A1 (0.55) TP53HTTALDH1A1MAPK1TSHR
SCHEMBL7908783 0.81 TSHR (0.55) TP53HTTALDH1A1TSHRATM
SCHEMBL13092259 0.79 ALDH1A1 (0.46) TP53HTTALDH1A1MAPK1TSHR
SCHEMBL13092239 0.76 ATM (0.46) TP53HTTALDH1A1HDAC3HDAC4
SCHEMBL7908651 0.76 KDM4E (0.43) TP53HTTALDH1A1HDAC3HDAC4
SCHEMBL13092219 0.75 ATM (0.46) TP53HTTALDH1A1HDAC3HDAC1
SCHEMBL13092550 0.74 SLC6A7 (0.46) TP53HTTALDH1A1MLYCDTSHR
SCHEMBL13092178 0.74 NPY1R (0.45) ALDH1A1MAPK1TSHRATM
SCHEMBL3091638 0.74 ATM (0.55) TP53HTTALDH1A1TSHRATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
WO-2010106081-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HTR3A, OPRL1, OPRK1 OGA 4683/4885TP53 3137/4885HTT 901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.